These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 29529345)

  • 1. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations.
    Milder DA; Milder TY; Kam PCA
    Anaesthesia; 2018 Aug; 73(8):1008-1018. PubMed ID: 29529345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 inhibitors in the peri-operative period: A warning to all clinicians.
    Waylen AL; Riedel B
    BJU Int; 2019 May; 123 Suppl 5():6-7. PubMed ID: 31116003
    [No Abstract]   [Full Text] [Related]  

  • 3. Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes.
    Milder TY; Greenfield JR; Milder DA
    Anaesthesia; 2023 Nov; 78(11):1418-1419. PubMed ID: 37329129
    [No Abstract]   [Full Text] [Related]  

  • 4. [Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].
    Breuer TGK; Kampmann K; Wutzler A; Steinfort C; Uhl W; Schmidt WE; Meier JJ
    Internist (Berl); 2018 Mar; 59(3):282-287. PubMed ID: 28864828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of perioperative discontinuation of SGLT2 inhibitors.
    Oosterom-Eijmael MJP; Hermanides J; van Raalte DH; Hulst AH
    Br J Anaesth; 2024 Aug; 133(2):239-240. PubMed ID: 38834489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose linked transporter 2 inhibitor associated post-operative euglycaemic diabetic ketoacidosis: an important consideration for all surgeons.
    Ahn T; Teloken P; Burke P
    ANZ J Surg; 2019 Jul; 89(7-8):982. PubMed ID: 31379074
    [No Abstract]   [Full Text] [Related]  

  • 7. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition.
    Sanusi I; Sarnowski A; Russell-Jones D; Forni LG
    J Crit Care; 2020 Jun; 57():19-22. PubMed ID: 32007835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol.
    Seki H; Kuratani N; Shiga T; Iwasaki Y; Karita K; Yasuda K; Yorozu T
    BMJ Open; 2021 Nov; 11(11):e049592. PubMed ID: 34815277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
    Thiruvenkatarajan V; Meyer EJ; Nanjappa N; Van Wijk RM; Jesudason D
    Br J Anaesth; 2019 Jul; 123(1):27-36. PubMed ID: 31060732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
    Peacock SC; Lovshin JA; Cherney DZI
    Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
    [No Abstract]   [Full Text] [Related]  

  • 11. [Not Available].
    Müssig K
    MMW Fortschr Med; 2024 Jun; 166(10):26-27. PubMed ID: 38806910
    [No Abstract]   [Full Text] [Related]  

  • 12. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
    Qiu H; Novikov A; Vallon V
    Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In brief: ketoacidosis with SGLT2 inhibitors.
    Med Lett Drugs Ther; 2015 Jun; 57(1471):94. PubMed ID: 26079766
    [No Abstract]   [Full Text] [Related]  

  • 14. [Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication].
    Rotsel E; Pietsch U
    Anaesthesist; 2020 Jan; 69(1):49-51. PubMed ID: 31807797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult.
    Nolan BJ; Varadarajan S; Fourlanos S; Neoh SL
    Am J Med; 2020 Aug; 133(8):e422-e424. PubMed ID: 31923401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering.
    Ceylan AF; Ren SY
    Curr Drug Targets; 2018; 19(9):1045-1050. PubMed ID: 29673309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature.
    Chacko B; Whitley M; Beckmann U; Murray K; Rowley M
    Anaesth Intensive Care; 2018 Mar; 46(2):215-219. PubMed ID: 29519226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
    Taylor SI; Blau JE; Rother KI; Beitelshees AL
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):949-958. PubMed ID: 31585721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
    Blau JE; Tella SH; Taylor SI; Rother KI
    Diabetes Metab Res Rev; 2017 Nov; 33(8):. PubMed ID: 28736981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.